Bcl3 Phosphorylation by Akt, Erk2, and IKK Is Required for Its Transcriptional Activity.

Unlike prototypical IκB proteins, which are inhibitors of NF-κB RelA, cRel, and RelB dimers, the atypical IκB protein Bcl3 is primarily a transcriptional coregulator of p52 and p50 homodimers. Bcl3 exists as phospho-protein in many cancer cells. Unphosphorylated Bcl3 acts as a classical IκB-like inhibitor and removes p50 and p52 from bound DNA. Neither the phosphorylation site(s) nor the kinase(s) phosphorylating Bcl3 is known. Here we show that Akt, Erk2, and IKK1/2 phosphorylate Bcl3. Phosphorylation of Ser33 by Akt induces switching of K48 ubiquitination to K63 ubiquitination and thus promotes nuclear localization and stabilization of Bcl3. Phosphorylation by Erk2 and IKK1/2 of Ser114 and Ser446 converts Bcl3 into a transcriptional coregulator by facilitating its recruitment to DNA. Cells expressing the S114A/S446A mutant have cellular proliferation and migration defects. This work links Akt and MAPK pathways to NF-κB through Bcl3 and provides mechanistic insight into how Bcl3 functions as an oncoprotein through collaboration with IKK1/2, Akt, and Erk2.

[1]  Hong-shan Wang,et al.  A role for the IkappaB family member Bcl-3 in the control of central immunologic tolerance. , 2007, Immunity.

[2]  A. Brasier,et al.  NF-κB-inducible BCL-3 Expression Is an Autoregulatory Loop Controlling Nuclear p50/NF-κB1 Residence* , 2001, The Journal of Biological Chemistry.

[3]  Shao-Cong Sun,et al.  NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. , 2003, Molecular cell.

[4]  J. Meléndez-Zajgla,et al.  Role of Bcl-3 in solid tumors , 2011, Molecular Cancer.

[5]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[6]  H. Stein,et al.  Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. , 2005, Blood.

[7]  Ramin Massoumi,et al.  Cyld Inhibits Tumor Cell Proliferation by Blocking Bcl-3-Dependent NF-κB Signaling , 2006, Cell.

[8]  H. Stein,et al.  Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas , 2005 .

[9]  R. Roskoski.  ERK1/2 MAP kinases: structure, function, and regulation. , 2012, Pharmacological research.

[10]  W. Muller,et al.  Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. , 2013, Cancer research.

[11]  E. Harhaj,et al.  Bcl-3 expression and nuclear translocation are induced by granulocyte-macrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors. , 1998, Blood.

[12]  R. Pathmanathan,et al.  Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. , 2003, Cancer research.

[13]  D. Green,et al.  GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. , 2004, Molecular cell.

[14]  W. Funkhouser,et al.  Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3 , 2000, Oncogene.

[15]  A. Hoffmann,et al.  The Transcriptional Specificity of NF-κB Dimers Is Coded within the κB DNA Response Elements , 2012, Cell reports.

[16]  P. Bamborough,et al.  The discovery of 2 -amino -3,5 -diarylbenzamide inhibitors of IKK-α and IKK-β kinases , 2007 .

[17]  A. Hoffmann,et al.  A Structural Basis for IκB Kinase 2 Activation Via Oligomerization-Dependent Trans Auto-Phosphorylation , 2013, PLoS biology.

[18]  J. Romashkova,et al.  NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. , 1999, Nature.

[19]  H. Ohno,et al.  Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor‐κB p52, which is associated with hyperphosphorylated Bcl‐3 , 2005, Cancer science.

[20]  C. Scheidereit,et al.  The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators , 1999, Oncogene.

[21]  M. Karin,et al.  BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins , 1994, Molecular and cellular biology.

[22]  A. Hoffmann,et al.  The Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of high-molecular-weight heterogeneous complexes. , 2009, Molecular cell.

[23]  P. Viatour,et al.  The Repressing Function of the Oncoprotein BCL-3 Requires CtBP, while Its Polyubiquitination and Degradation Involve the E3 Ligase TBLR1 , 2010, Molecular and Cellular Biology.

[24]  P. Bamborough,et al.  The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK-alpha and IKK-beta kinases. , 2007, Bioorganic & medicinal chemistry letters.

[25]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[26]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[27]  M. Waterman,et al.  TCF/LEFs and Wnt signaling in the nucleus. , 2012, Cold Spring Harbor perspectives in biology.

[28]  S. Westerheide,et al.  The Putative Oncoprotein Bcl-3 Induces Cyclin D1 To Stimulate G1 Transition , 2001, Molecular and Cellular Biology.

[29]  M. Merville,et al.  Protein Phosphorylation as a Key Mechanism for the Regulation of BCL-3 Activity , 2004, Cell cycle.

[30]  J. Romashkova,et al.  NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.

[31]  A. Brasier,et al.  NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence. , 2001, The Journal of biological chemistry.

[32]  H. Ohno,et al.  The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control , 1990, Cell.

[33]  H. Ohno,et al.  High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. , 2003, Blood.

[34]  J. Caamaño,et al.  Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo , 1996, Molecular and cellular biology.

[35]  Yu Xue,et al.  GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. , 2011, Protein engineering, design & selection : PEDS.

[36]  Paul R Thompson,et al.  Kinase consensus sequences: a breeding ground for crosstalk. , 2011, ACS chemical biology.

[37]  W. Funkhouser,et al.  Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. , 2000, Oncogene.

[38]  T. McKeithan,et al.  Diverse Effects of BCL3 Phosphorylation on Its Modulation of NF-κB p52 Homodimer Binding to DNA* , 1997, The Journal of Biological Chemistry.

[39]  G. Nolan,et al.  The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. , 1993, Genes & development.

[40]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[41]  T. McKeithan,et al.  Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. , 1993, Leukemia.